Pharmaceutical Executive February 13, 2025
Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis.
Novartis announced that it has agreed to terms to acquire Anthos Therapeutics for an upfront payment of $925 million. The deal will include abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients with atrial fibrillation and cancer-associated thrombosis. Originally licensed from Novartis, abelacimab has demonstrated a significant reduction in bleeding risk compared to standard anticoagulants in Phase II trials and is currently being evaluated in three Phase III studies.1
“We are excited to join forces to advance the development of abelacimab, a potential first-in-class treatment and safer approach for stroke prevention in atrial fibrillation as...
Today's Sponsors
Today's Sponsor